We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax Vaccine to Get U.S. Approval? ETFs to Benefit
Read MoreHide Full Article
Novavax (NVAX - Free Report) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.According to a report by Politico, there is hope that the Novavax vaccine can boost supplies, as both safety and production issues weigh on the Johnson & Johnson (JNJ - Free Report) and AstraZeneca (AZN - Free Report) shots.
In March 2021, the company offered impressive updates on its protein-based COVID-19 vaccine candidate, NVX-CoV2373. The company’s vaccine candidate has delivered the final efficacy of 96.4% in a pivotal Phase 3 trial in the U.K., against mild, moderate and severe diseases caused by the original COVID-19 strain.
About two months back, the company projected to receive data from a 30,000-people trial in the United States and Mexico by the end of this month. In a U.K. trial, the Novavax vaccine came out as effective as the mRNA shots pf Pfizer and Modena.
This piece of information makes it clear why Novavax is said to be on the verge of receiving the approval for emergency use as early as May, per a CNBC article. However, the timeline could be delayed by one or two months if the FDA plans to wait for the U.S.-based trial data, Novavax CEO said.
South Korean firmSK Bioscience will produce 40 million doses of the Novavax vaccine this year. The Novavax vaccine will help stop the likely supply crunch in the coming months as is being seen in the United States, European nations, and India. Interestingly, Novavax has never launched a product to market and if approved, the COVID-19 vaccine would be its first commercial success.
The best part is that the Novavax vaccine does not need extremely freezing temperature for storage, unlike vaccines developed by Pfizer and Moderna (MRNA). Hence, the Novavax vaccine’s commercial success looks to be sure thing, if it doesn’t trigger any safety issue over the long run.
Market Impact
Novavax shares jumped 15% in the past five days against 0.2% gains in the S&P 500. If the company gets EUA in the United States soon, we expect further rally ahead in the stock. Novavax has considerable weightin some ETFs. Understandably, those ETFs will also gain.
ETFMG Treatments Testing and Advancements ETF (GERM - Free Report) – 5% weight in Novavax
Image: Bigstock
Novavax Vaccine to Get U.S. Approval? ETFs to Benefit
Novavax (NVAX - Free Report) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.According to a report by Politico, there is hope that the Novavax vaccine can boost supplies, as both safety and production issues weigh on the Johnson & Johnson (JNJ - Free Report) and AstraZeneca (AZN - Free Report) shots.
History Behind the Vaccine
Novavax started the first human study of the vaccine on May 25. On Dec 28, the drugmaker started a phase 3 clinical trial for its COVID-19 vaccine, making it the fifth drugmaker to enter phase 3 trials for a COVID-19 vaccine in the United States. In July, the U.S. granted $1.6 billion to Novavax to support its COVID-19 vaccine candidate. The drugmaker has assured that it will deliver 100 million doses of the vaccine to the county.
In March 2021, the company offered impressive updates on its protein-based COVID-19 vaccine candidate, NVX-CoV2373. The company’s vaccine candidate has delivered the final efficacy of 96.4% in a pivotal Phase 3 trial in the U.K., against mild, moderate and severe diseases caused by the original COVID-19 strain.
About two months back, the company projected to receive data from a 30,000-people trial in the United States and Mexico by the end of this month. In a U.K. trial, the Novavax vaccine came out as effective as the mRNA shots pf Pfizer and Modena.
This piece of information makes it clear why Novavax is said to be on the verge of receiving the approval for emergency use as early as May, per a CNBC article. However, the timeline could be delayed by one or two months if the FDA plans to wait for the U.S.-based trial data, Novavax CEO said.
South Korean firmSK Bioscience will produce 40 million doses of the Novavax vaccine this year. The Novavax vaccine will help stop the likely supply crunch in the coming months as is being seen in the United States, European nations, and India. Interestingly, Novavax has never launched a product to market and if approved, the COVID-19 vaccine would be its first commercial success.
The best part is that the Novavax vaccine does not need extremely freezing temperature for storage, unlike vaccines developed by Pfizer and Moderna (MRNA). Hence, the Novavax vaccine’s commercial success looks to be sure thing, if it doesn’t trigger any safety issue over the long run.
Market Impact
Novavax shares jumped 15% in the past five days against 0.2% gains in the S&P 500. If the company gets EUA in the United States soon, we expect further rally ahead in the stock. Novavax has considerable weightin some ETFs. Understandably, those ETFs will also gain.
ETFMG Treatments Testing and Advancements ETF (GERM - Free Report) – 5% weight in Novavax
VanEck Vectors Biotech ETF (BBH - Free Report) – 4.69% weight in Novavax
VanEck Vectors Social Sentiment ETF (BUZZ - Free Report) – 2.96% weight in Novavax
Other broader biotech ETFs and some COVID-19-themed ETFs can also include the stock if it gets an FDA approval soon. These ETFS could be:
iShares Nasdaq Biotechnology ETF (IBB - Free Report)
SPDR S&P Biotech ETF (XBI - Free Report)
The Pacer Bio Threat ETF (VIRS - Free Report)
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>